Peptide Categories Explained
With dozens of research peptides available, understanding the major categories and how they differ is essential for choosing the right compound for your research goals. This reference guide breaks down each category by mechanism of action, key peptides, research applications, and what the current evidence shows.
Key Takeaways
- GLP-1 receptor agonists have the strongest evidence base with multiple FDA-approved peptides and large clinical trials
- Growth hormone secretagogues are well-studied with some FDA approvals, offering a natural approach to GH optimization
- Healing peptides like BPC-157 have impressive animal data but lack controlled human trials
- Cognitive peptides have some human clinical data primarily from Russian institutions but lack FDA approval
- Anti-aging peptides target fascinating mechanisms but generally have the weakest evidence base for human use
Growth Hormone Secretagogues
Growth hormone secretagogues stimulate the pituitary gland to produce and release more growth hormone through the body's natural pathways. This approach differs from exogenous growth hormone injection because it preserves the natural pulsatile release pattern and feedback mechanisms. Key peptides in this category include Ipamorelin (selective GH release with minimal side effects), CJC-1295 (stimulates GHRH receptor, often paired with Ipamorelin), and Tesamorelin (FDA-approved for HIV lipodystrophy). Research applications focus on body composition, recovery, sleep quality, and anti-aging. The evidence base is strong, with Tesamorelin having full FDA approval and Ipamorelin having extensive clinical trial data.
GLP-1 Receptor Agonists and Weight Management
GLP-1 receptor agonists mimic the incretin hormone GLP-1 to regulate appetite, blood sugar, and metabolic function. This is currently the most commercially successful peptide category. Semaglutide (Ozempic/Wegovy) and Tirzepatide (Mounjaro/Zepbound) are FDA-approved blockbusters with extensive clinical trial data showing 15-25% body weight reduction. Retatrutide is a triple agonist (GLP-1/GIP/glucagon) in late-stage trials. CagriSema combines semaglutide with amylin analog cagrilintide. Orforglipron is notable as a non-peptide oral GLP-1 agonist. This category has the strongest evidence base of any peptide class.
Healing and Recovery Peptides
Healing peptides promote tissue repair, reduce inflammation, and accelerate recovery from injury. BPC-157 (Body Protection Compound) is the most popular, with extensive animal data showing remarkable healing properties across multiple tissue types including tendons, ligaments, muscles, and gut lining. TB-500 (Thymosin Beta-4 fragment) promotes cell migration and wound healing. GHK-Cu (copper peptide) stimulates collagen production, wound healing, and has anti-inflammatory properties. The major caveat for this category is that most evidence comes from animal studies, with very limited controlled human trial data, particularly for BPC-157.
Cognitive Enhancement Peptides
Cognitive peptides modulate neurotransmitter systems to influence focus, memory, mood, and neuroprotection. Semax, developed in Russia, enhances BDNF expression and has been shown to improve attention and memory in clinical studies. Selank, also Russian-developed, acts on GABA and serotonin systems with anxiolytic and cognitive-enhancing properties. Both are approved medications in Russia with published clinical data, though they lack FDA approval. Dihexa is a newer compound with potent BDNF-mimetic activity but very limited human data. This category occupies a middle ground in evidence, with some human clinical data primarily from Russian institutions.
Anti-Aging and Longevity Peptides
Anti-aging peptides target fundamental mechanisms of cellular aging. Epitalon activates telomerase, potentially slowing telomere shortening associated with aging. FOXO4-DRI is a senolytic peptide that selectively induces apoptosis in senescent cells. MOTS-c is a mitochondrial-derived peptide that improves metabolic function and has been called an exercise mimetic. 5-Amino-1MQ inhibits NNMT enzyme to boost NAD+ levels and metabolic function. This category contains some of the most scientifically fascinating compounds but generally has the weakest evidence base, with most data from animal models and mechanistic studies rather than large-scale human trials.
Frequently Asked Questions
Which peptide category has the most evidence behind it?
GLP-1 receptor agonists have the strongest evidence by far. Semaglutide and Tirzepatide have completed multiple large-scale Phase III clinical trials with thousands of participants, received FDA approval, and continue to accumulate real-world data from millions of users. Growth hormone secretagogues are second, with Tesamorelin holding FDA approval.
Can peptides from different categories be combined?
Some researchers do combine peptides from different categories (called stacking), but this significantly increases complexity and risk. Interactions between peptides are often poorly studied. If you are new to peptide research, work with a single compound until you fully understand its individual effects before considering combinations. When stacking, only combine compounds with established safety profiles.
Are there peptides that fit multiple categories?
Yes. Some peptides have effects spanning multiple categories. For example, Tesamorelin is both a growth hormone secretagogue and has cognitive enhancement research data. BPC-157 affects healing, gut health, and has some neuroprotective data. MOTS-c bridges metabolic health and anti-aging categories. The categories are useful organizational tools but do not represent rigid boundaries.